Summary
Vertex Pharmaceuticals Incorporated (VRTX) has announced a significant transaction involving the exchange of its Convertible Subordinated Notes due 2007 for newly issued shares of common stock. On September 8, 2005, the company entered into agreements with noteholders to exchange approximately $40.5 million in principal amount of these notes, along with accrued interest, for 2,451,980 shares of VRTX common stock. This transaction was completed on September 9, 2005. While the exchange strengthens the company's balance sheet by reducing debt, investors should note the associated financial implications. Vertex expects to record a non-cash charge of approximately $36.0 million in its third quarter 2005 results. This charge stems from the incremental shares issued beyond what would have been delivered upon a standard conversion of the notes under their original terms. The company has filed this information via an 8-K, with the exchange being exempt from registration under the Securities Act of 1933.
Key Highlights
- 1Vertex Pharmaceuticals exchanged $40.5 million of its Convertible Subordinated Notes due 2007 for approximately 2.45 million shares of common stock.
- 2The exchange transaction was completed on September 9, 2005.
- 3The company anticipates a non-cash charge of roughly $36.0 million in Q3 2005 related to this exchange.
- 4This non-cash charge is due to issuing shares in excess of the number required by the original note conversion terms.
- 5The exchange of securities was exempt from registration under Section 3(a)(9) of the Securities Act of 1933, involving existing security holders.
- 6A press release dated September 9, 2005, detailing the exchange and its financial impact, was filed as an exhibit.